Testosterone Enanthate
FDA-approved product (injectable, injection), marketed as Delatestryl, Testosterone Enanthate, Xyosted (Autoinjector).
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cancer
- Hypogonadism
- Hypogonadotropic hypogonadism
- Klinefelter's syndrome
- Neoplasm
- Orchitis
- Physiological sexual disorder
- Sexual dysfunction
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- 3-oxoandrosten (4) derivatives
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA51.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli28.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis24.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Testosterone Enanthate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Trimetrexate GlucuronateExisting use: Other agents against amoebiasis and other protozoal diseases88.6% AI-predicted activityagainst E. coliLab records exist17 registered studies
- Folic AcidExisting use: Acne, Anemia, Anemia (phenotype) and 8 more87.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more86.8% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- PralatrexateExisting use: Cancer, Mature T-cell and NK-cell non-Hodgkin lymphoma, Neoplasm and 2 more82.2% AI-predicted activityagainst E. coli44 registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives81.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Leucovorin CalciumExisting use: Osteosarcoma67.6% AI-predicted activityagainst E. coli50+ registered studies
- LevoleucovorinExisting use: Anemia, Colorectal adenocarcinoma, Colorectal cancer and 3 more67.6% AI-predicted activityagainst E. coli50+ registered studies
- PyrimethamineExisting use: Malaria, Toxoplasmosis64.6% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Copanlisib DihydrochlorideExisting use: Follicular lymphoma, Neoplasm, Neoplasm of mature B-cells63.5% AI-predicted activityagainst E. coli10 registered studies
- AfamelanotideExisting use: Erythropoietic protoporphyria62.6% AI-predicted activityagainst E. coli23 registered studies
- Rimegepant SulfateExisting use: Migraine disorder61.6% AI-predicted activityagainst E. coli50+ registered studies
- Histrelin AcetateExisting use: Neoplasm, Prostate adenocarcinoma, Prostate cancer61.6% AI-predicted activityagainst E. coli13 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Muscle Anabolic Interventions to Accelerate Recovery From Hospitalization in Geriatric Patients
NCT02990533 · start 2016-09
Registered record
- Registry ID
- NCT02990533
- Conditions
- Aging
- Interventions
- Testosterone; Protein Supplement; Placebo Injection; Placebo supplement
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2016-09
- Completion
- 2020-11-08
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAgingInterventionTestosterone; Protein Supplement; Placebo Injection; Placebo supplementPhasePhase 1Registry statusCompletedSafety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism
NCT02777242 · start 2016-06
Registered record
- Registry ID
- NCT02777242
- Conditions
- Hypogonadism
- Interventions
- Testosterone enanthate auto-injector
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2016-06
- Completion
- 2016-08
- Enrolment
- 66
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadismInterventionTestosterone enanthate auto-injectorPhasePhase 2Registry statusCompletedPhysiological and Psychological Effects of Testosterone During Severe Energy Deficit and Recovery
NCT02734238 · start 2016-04
Registered record
- Registry ID
- NCT02734238
- Conditions
- Caloric Restriction; Exercise
- Interventions
- Sesame Oil; testosterone enanthate
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2016-04
- Completion
- 2017-12
- Enrolment
- 53
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCaloric Restriction; ExerciseInterventionSesame Oil; testosterone enanthatePhasePhase 4Registry statusCompletedCycled Testosterone Therapy to Improve Physical Function in Frail Nursing Home Residents
NCT02679274 · start 2016-02-16
Registered record
- Registry ID
- NCT02679274
- Conditions
- Aging
- Interventions
- Placebo; Testosterone
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Terminated
- Start
- 2016-02-16
- Completion
- 2016-09-20
- Enrolment
- 3
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAgingInterventionPlacebo; TestosteronePhaseEarly phase 1Registry statusTerminatedThe Effects of Long Term Cyclic Testosterone Administration on Muscle Function and Bone in Older Men
NCT01417364 · start 2016-01
Registered record
- Registry ID
- NCT01417364
- Conditions
- Sarcopenia
- Interventions
- Testosterone enanthate; Testosterone enanthate; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Withdrawn
- Start
- 2016-01
- Completion
- 2017-12
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSarcopeniaInterventionTestosterone enanthate; Testosterone enanthate; PlaceboPhasePhase 4Registry statusWithdrawnSubcutaneous Testosterone Project
NCT02229617 · start 2015-07
Registered record
- Registry ID
- NCT02229617
- Conditions
- Gender Dysphoria
- Interventions
- Subcutaneous testosterone
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2015-07
- Completion
- 2016-05
- Enrolment
- 14
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGender DysphoriaInterventionSubcutaneous testosteronePhasePhase 1 / Phase 2Registry statusCompletedSubcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
NCT02504541 · start 2015-07
Registered record
- Registry ID
- NCT02504541
- Conditions
- Hypogonadism
- Interventions
- Testosterone enanthate auto-injector
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2015-07
- Completion
- 2016-06
- Enrolment
- 133
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadismInterventionTestosterone enanthate auto-injectorPhasePhase 3Registry statusCompletedTestosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance
NCT02286921 · start 2015-01
Registered record
- Registry ID
- NCT02286921
- Conditions
- Castration Resistant Metastatic Prostate Cancer
- Interventions
- Testosterone cypionate; Enzalutamide; Testosterone Enanthate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2015-01
- Completion
- 2020-02-21
- Enrolment
- 222
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCastration Resistant Metastatic Prostate CancerInterventionTestosterone cypionate; Enzalutamide; Testosterone EnanthatePhasePhase 2Registry statusCompletedOral Testosterone for the Treatment of Hypogonadism in Males
NCT02222558 · start 2014-09
Registered record
- Registry ID
- NCT02222558
- Conditions
- Hypogonadism
- Interventions
- TSX-002
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2014-09
- Completion
- 2015-05
- Enrolment
- 25
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadismInterventionTSX-002PhasePhase 2Registry statusCompletedPharmacokinetic Study of Subcutaneous Testosterone Enanthate
NCT02233751 · start 2014-09
Registered record
- Registry ID
- NCT02233751
- Conditions
- Hypogonadism
- Interventions
- Testosterone enanthate auto-injector
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2014-09
- Completion
- 2014-10
- Enrolment
- 12
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadismInterventionTestosterone enanthate auto-injectorPhasePhase 1Registry statusCompletedRE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)
NCT02090114 · start 2014-08-25
Registered record
- Registry ID
- NCT02090114
- Conditions
- Prostate Cancer
- Interventions
- Testosterone cypionate; Testosterone Enanthate; Abiraterone acetate; Enzalutamide
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2014-08-25
- Completion
- 2021-11-11
- Enrolment
- 112
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionTestosterone cypionate; Testosterone Enanthate; Abiraterone acetate; EnzalutamidePhasePhase 2Registry statusCompletedSubcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism
NCT02159469 · start 2014-07
Registered record
- Registry ID
- NCT02159469
- Conditions
- Hypogonadism
- Interventions
- Testosterone enanthate auto-injector
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2014-07
- Completion
- 2015-11
- Enrolment
- 150
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadismInterventionTestosterone enanthate auto-injectorPhasePhase 3Registry statusCompletedPubertal Replacement In Boys Study Nebido and Testoviron Depot Treatment
NCT05417035 · start 2014-06-01
Registered record
- Registry ID
- NCT05417035
- Conditions
- Puberty Delayed
- Interventions
- Nebido
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2014-06-01
- Completion
- 2020-08-01
- Enrolment
- 27
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPuberty DelayedInterventionNebidoPhaseNot applicableRegistry statusCompletedA Study to Evaluate a Skeletal-muscle Microbiopsy Technique With Dynamic Proteomic Measurement in Healthy Male Volunteers
NCT01962454 · start 2014-05-05
Registered record
- Registry ID
- NCT01962454
- Conditions
- Cachexia
- Interventions
- Deuterated Water; Testosterone enanthate; Placebo to match testosterone enanthate
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2014-05-05
- Completion
- 2015-03-20
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCachexiaInterventionDeuterated Water; Testosterone enanthate; Placebo to match testosterone enanthatePhasePhase 1Registry statusCompletedSafety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism
NCT02081300 · start 2014-02
Registered record
- Registry ID
- NCT02081300
- Conditions
- Male Hypogonadism
- Interventions
- Oral testosterone undecanoate, LPCN 1021; Topical testosterone gel 1.62 %
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2014-02
- Completion
- 2015-05
- Enrolment
- 315
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMale HypogonadismInterventionOral testosterone undecanoate, LPCN 1021; Topical testosterone gel 1.62 %PhasePhase 3Registry statusCompleted